Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

BACKGROUND: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in patients with a smoking history and prompted us to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Dafni, U., Soo, R.A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J.-Y., De Castro, J., Coate, L., Früh, M., Hashemi, S.M.S., Nadal, E., Carcereny, E., Sala, M.A., Bernabé, R., Provencio, M., Cuffe, S., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271510/
https://www.ncbi.nlm.nih.gov/pubmed/35696746
http://dx.doi.org/10.1016/j.esmoop.2022.100507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271510/
https://www.ncbi.nlm.nih.gov/pubmed/35696746
http://dx.doi.org/10.1016/j.esmoop.2022.100507

Ejemplares similares